Regulus Therapeutics (United States)
Regulus Therapeutics Inc. or Regulus is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Regulus Therapeutics (United States), United States, covering academic research published from 2008 to 2023. Read More.
Open Access Percentage
59%
Total
Publications
157
Total Open
Publications
92
Total
Citations
19K
Open Access
Percentage
59%
Total
Publications
157
Total Open
Publications
92
Total
Citations
19K
Breakdown
Publisher Open
8%
Both
34%
Other Platform Open
16%
Closed
42%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 28%
19
Hybrid 27%
18
No Guarantees 45%
30
Other Platform Open
Domain 89%
70
Institution 30%
24
Public 19%
15
Other Internet 18%
14
Preprint 5%
4
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 70 |
Europe PMC | Domain | 62 |
DOI | Other Internet | 28 |
Semantic Scholar | Public | 10 |
Figshare | Public | 8 |
California Digital Library - eScholarship | Other Internet | 7 |
California Institute of Technology - CaltechAUTHORS | Institution | 6 |
Harvard University - Digital Access to Scholarship at Harvard (DASH) | Institution | 5 |
bioRxiv | Preprint | 4 |
Le Centre pour la Communication Scientifique Directe - HAL - Diderot | Institution | 3 |